PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
出版年份 2019 全文链接
标题
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
作者
关键词
Breast cancer, PD-L1, Biomarker, Prognostic, Immunohistochemistry
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-01-10
DOI
10.1007/s10549-019-05130-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer
- (2018) Seo Hee Choi et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
- (2018) Ming Li et al. BMC CANCER
- Checkpoint inhibitors in breast cancer – Current status
- (2018) Anne Polk et al. CANCER TREATMENT REVIEWS
- Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy
- (2018) Yanjun Hou et al. Clinical Breast Cancer
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders
- (2018) Mai F. Tolba et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
- (2018) Margarita Udall et al. Diagnostic Pathology
- PD-L1 in breast cancer: comparative analysis of 3 different antibodies
- (2018) Tejashree Karnik et al. HUMAN PATHOLOGY
- Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer
- (2018) Yunxuan Wang et al. Journal of Breast Cancer
- Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters
- (2018) Zhandong Wang et al. Journal of Cancer Research and Therapeutics
- Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial
- (2018) Vasiliki Pelekanou et al. MOLECULAR CANCER THERAPEUTICS
- Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes
- (2018) Karin Zins et al. Oncotarget
- A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma
- (2018) Tadashi Sakane et al. Oncotarget
- Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
- (2018) Megan B. Barnet et al. Journal of Clinical Medicine
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients
- (2017) NiJiati AiErken et al. International Journal of Biological Sciences
- Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
- (2017) Gerardo Botti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
- (2017) António Polónia et al. JOURNAL OF CLINICAL PATHOLOGY
- Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer
- (2017) Thomas A Adams et al. MODERN PATHOLOGY
- Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
- (2017) Thomas J Gniadek et al. MODERN PATHOLOGY
- Current status and perspectives in immunotherapy for metastatic melanoma
- (2017) Riccardo Marconcini et al. Oncotarget
- PD-L1 and intratumoral immune response in breast cancer
- (2017) Zhi-Qiang Wang et al. Oncotarget
- Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
- (2017) Minghui Zhang et al. Oncotarget
- The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
- (2017) Hitomi Mori et al. Oncotarget
- An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
- (2017) Lauren E. McLemore et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
- (2017) Bruna Cerbelli et al. Biomed Research International
- Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma
- (2017) Jian Lou et al. Open Medicine
- Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
- (2017) Ahrong Kim et al. Scientific Reports
- Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
- (2016) Rin Ogiya et al. CANCER SCIENCE
- Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer
- (2016) In Hae Park et al. Clinical Breast Cancer
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
- (2016) Rhiannon K Beckers et al. HISTOPATHOLOGY
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Prognostic significance of PD-L1 and PD-L2 in breast cancer
- (2016) Mauricio Z. Baptista et al. HUMAN PATHOLOGY
- Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer
- (2016) Sang Byung Bae et al. Journal of Breast Cancer
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1
- (2016) Upasana Joneja et al. JOURNAL OF CLINICAL PATHOLOGY
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
- (2016) Woo Young Sun et al. Journal of Translational Medicine
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient
- (2016) Zhenhua Li et al. Journal of Cancer
- Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer
- (2016) Laurence Buisseret et al. OncoImmunology
- PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
- (2016) Lei Guo et al. SpringerPlus
- PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
- (2015) H. R. Ali et al. ANNALS OF ONCOLOGY
- Clinical implications of the intrinsic molecular subtypes of breast cancer
- (2015) Aleix Prat et al. BREAST
- Prognostic and predictive immune gene signatures in breast cancer
- (2015) Davide Bedognetti et al. CURRENT OPINION IN ONCOLOGY
- Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression
- (2015) M. C. U. Cheang et al. ONCOLOGIST
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
- (2014) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- PD-L1 expression and tumor-infiltrating lymphocytes
- (2014) Kurt A Schalper OncoImmunology
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation